Generic Injectable Market (By Product Type: Chemotherapy agents, Small molecule antibiotics, Vaccines, Peptide antibiotics, Blood factors, Peptide hormone, Insulin, Cytokines, Immunoglobin, Monoclonal Antibodies; By Molecular Type: Small Molecule, Large Molecule; By Application; By Administration; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022-2030


The global generic injectable market size was estimated at USD 94.3 billion in the year 2021 and is expected to reach around USD 309.1 billion by 2030. The generic injectable market is growing at a CAGR of 14.1% during the forecast period driven by increased demand for generic drugs from the health care sector and the customers enhanced.

Generic Injectable Market Size 2022 To 2030

Key Takeaway:

  • The large molecule type segment has held 69% revenue share in 2021.
  • The small molecule segment accounted 31% market share in 2021.
  • North America region has dominated the market with revenue share of around 46% in 2021.

The generic injectable drug is the compound having therapeutic characteristics with increased efficiency, potent. Which focus to kill the disease or the chronic infection. The generic drug basically is the chemical substance with increased developments and continuous research have increased the availability of the generic drugs in the market with fast approval of the drug. There are two categorisation involves generic drug and branded drug. Generic drug is basically same with the branded drug with same active pharmaceutical ingredient, with equal safety, quality, strength, efficiency, output of the drug, route of administration is same of both generic and branded drugs. 

Therefore, increased focus on producing and manufacturing the generic drug with increased efficiency and decreased adverse drug reactions of the generic drugs. Increased chronic diseases among the population with increased medications enhanced the market of generic injectable drugs. Changing lifestyle of the people with increased diseases strives the market growth. Increased various new launch of the generic drugs as that of branded drugs with expiry of patents which reduced the new launch of the drug. Which helps to boost the market of generic injectable.

Impact of covid-19 viral disease, wide spread of virus across the regions with increase patient hospitalisation rate with increased demand for the drugs which fuels the market growth of generic drugs with cost effective benefit from the generic drugs.

Report Scope of the Generic Injectable Market

Report Coverage Details
Market Size in 2022

USD 107.6 Billion

Market Size by 2030

USD 309.1 Billion

Growth Rate from 2022 to 2030 CAGR of 14.1%
Base Year 2021
Forecast Period 2022 to 2030
Segments Covered Product Type, Molecular Type, Application, Administration, Distribution Channel, and Geography
Companies Mentioned DR. Reddys Laboratries Ltd, Baxter International, Mylan N.A, Teva Pharmaceuticals, Astra Zeneca Plc, Sanofi S.A, Fresenius Kabi, Pfizer Inc, Cipla Ltd, Merck & Co. Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Limited, Samsung Biologics Co Ltd, Biocon, Lupin,Ltd, Astrazeneca, GlaxoSmithKline Plc, Hikma Pharmaceuticals, Cosette Pharmaceutical, Inc, Johnson & Johnson Services, Inc, Sanofi SA, Amgen Inc., Bristol- Myers Squibb Company, Piramal Pharma Solutions, Merck KGaA

 

Growth Factors

The advanced developed drugs with increased efficacy of the drugs with increased research and development for producing the new generic drugs with fast approval of the new drug for increasing chronic diseases across the regions with increased adoption of the new lifestyle and habitual has increased the number of diseases, different dietary intake which is the major factor of increasing the disease. Increasing population with increasing infectious disease which led to short of generic injectable drugs which increased production of the generic drugs enhanced the market to grow at a larger extend.

Generic injectable drugs are less expensive than the branded drugs with increased cost of the drugs. Generic drug is highly affordable for the customers with very low cost of the drugs. Which led to increased demands from the health care sector for the generic injectable with increased efficacy and therapeutic index. Expansion of the generic injectable with various developments in routes of administration with increased research and developments in generic drugs drives the market of generic injectable with increased demand. Brand injectable comes with the expiry of the patent therefore reduced the number of introductions of the new drugs. Which led to increase research, production and manufacturing of the generic injectables fuels the market growth.

Research and development steps are less than branded drugs with fast approval and production of the generic injectable with increased demand from the health care sector expanded the market growth. The key market players involved in introducing the new generic drugs with increased investment for research and developed helps to boost the market growth at a larger extent during the forecast period. Increased government interest in developing the generic injectables due to decreased launch of the generic drugs and low cost of the generic with increased investment have rise the market to grow high.

Key Market Drivers

Rising prevalence of chronic infectious diseases

Increased population in the regions with increased infectious diseases among the people which led to increased number of patients for hospitalization with increased demand for the generic injectable drugs. Branded drugs come with patent expiry with decreased launch of the new generic injectable drug therefore expanded the demand for the generic injectables with similar efficacy, quality, strength, potent, safety. Which boosts the generic injectable market to a greater extend.

Cost effectivity of the generic injectables

  • Low cost of the generic injectables drugs with increased demand from the health care sector with increased affordability for the consumers with increased facility and increased number of treatments with low cost have enhance the market growth at a larger extent. The cost effectivity is the major reason for striving the growth of the generic injectable with increased manufacturing and producing of the generic drugs with similar efficacy, quality, strength, good patient response, increased therapeutic index.
  • Increased research and development for introducing new developments for the infectious diseases with less number of step than that of branded drugs. Fast approval of the new drug with increased production and manufacturing of the drugs supports to fuel the market of injectable drugs with increased demand from the health care centre. Branded injectables with patent expiry with reduced developing of the new injectables which led to developing of the generic injectables.

Key Market Challenges 

  • Increased cost for processing of the generic injectables - Rising cost of the generic injectables for producing and manufacturing of the drug with increased equipment cost for processing of the active compound with increased care management during the processing of the generic injectable drug. Increased manufacturing producing, packing, storage of the generic drug. With increased cleanliness with increased sterilization to avoid bacterial, fungal contamination to the generic drug. Which contributes for increased stability for the generic drugs. Cost issues can challenge the generic market to grow during the forecast period.
  • Lack of skill- Lack of skill for producing the generic injectables with increased research and development with new technology and new skills for development of the generic injectables lack of skill may hamper the market growth of generic injectables.
  • Availability of other drugs - Availability of other injectable drugs other than generic with increased options for adopting the treatment can decrease the market growth during the forecast period.

Key Market Opportunities

  • Increased manufacturing and developments of generic injectables - Increased manufacturing and producing of the injectables with increased research with improved efficacy, safety, quality of the drug, output of the drug contributes for increasing the market with increased requirement for the new development of the generic drugs with increased sterilization to prevent from microbial attack. Which fuels the growth of generic injectable market. Enhanced study of pharmacokinetics and pharmacodynamics of the generic injectables which expands the market growth to a larger extend.
  • The key market players - The key market players involved in introducing new technology with increased development of the generic injectables with increased investment for producing the new generic injectables strives the market to grow high with increased demand from the health care centre with increased technology.

Segment Insights

Product Type Insight

Monoclonal antibodies to hold the highest market share with increased revenue during the forecast period of generic injectables.

Molecule Type Insight

Increased research and development in large molecules for developing the generic injectables with increased opportunity and increased share in the market.

Generic Injectable Market Share, By Molecular, 2021 (%)

Which helps to increase the market of generic injectables. However, the small molecule segment is poised to grow at a higher CAGR during the forecast period 2022 to 2030.

Application Insight

Increased growth of the diabetes disease with increased life style and dietary supplements with high rate of patients among the population due to the previous family or increased obesity. Which led to increase of the diabetes with increased demand for the generic injectables. Oncology is also rising from the year 2021 with increased chemotherapies and generic injectables with high demand for the medication from the health care centre. However, the diabetes segment is growing at the strongest CAGR from 2022 to 2030.

Distribution Channel Insight

Segmentation of generic injectables based on distribution channel involves Hospital pharmacy, retail pharmacy, drug stores and online pharmacy. Due to increased chronic infectious diseases with enlargement of the hospitals with their own hospital pharmacy increase growth of the hospital across the regions. Hospital pharmacy to hold the largest market.

Generic Injectable Market Share, By Region, 2021 (%)

Regions Revenue Share in 2021 (%)
North America 46%
Asia Pacific 19%
Europe 27%
Latin America 5%
MEA 3%

 

Geography Insight

Segmentation of generic injectables based on geography sector North America to be the leading region with highest market growth of the generic injectables with increased development of the generic injectables with increased research and development from the key market players for introducing the generic injectables with increased demand from the health care center due to shortage of the injectable with increased chronic infectious diseases among the population with increased hospitalization rate of the patients.

Asia pacific region also helps to boost the market growth with increased demand from the health care centre for generic injectables with increased chronic diseases increasing due to rising population. Other regions such as Europe, Latin America, Middle East and Africa contributes to increase the market of generic injectables to a larger extend.

Recent Developments

  • Prochlorperazine Edisylate drug infusion a drug from the Cosette Pharmaceutical Inc, which is identical drug to another drug such as Compazine injection 10mg/2ml. Prochlorperazine Edisyalte is utilised to manage the queasiness and retching. Prochlorperazine is also utilized in controlling schizoprenia.
  • In the year 2022 March, Collaboration of Midatech Pharma and Johnson & Johnsons Pharmaceuticals in the year 2020 July. Increased drug delivery technology with the aim of bio delivery increased research and development in biodistribution.
  • In the year 2022 January, Hikma Pharmaceutical for US introduced the new 503B, a new sterile drug with increased business with increased effectivity, quality, injectables, and other increased medications.

Key Market Players

  • DR. Reddys Laboratries Ltd
  • Baxter International
  • Mylan N.A
  • Teva Pharmaceuticals
  • Astra Zeneca Plc
  • Sanofi S.A
  • Fresenius Kabi
  • Pfizer Inc
  • Cipla Ltd
  • Merck & Co. Inc
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd
  • Aurobindo Pharma Limited
  • Samsung Biologics Co Ltd
  • Biocon
  • Lupin,Ltd
  • Astrazeneca
  • GlaxoSmithKline Plc
  • Hikma Pharmaceuticals
  • Cosette Pharmaceutical, Inc
  • Johnson & Johnson Services, Inc
  • Sanofi SA
  • Amgen Inc.
  • Bristol- Myers Squibb Company
  • Piramal Pharma Solutions
  • Merck KGaA

Segments Covered in the Report

(Note*: We offer report based on sub segments as well. Kindly, let us know if you are interested)

By Product Type

  • Chemotherapy agents 
  • Small molecule antibiotics 
  • Vaccines 
  • Peptide antibiotics 
  • Blood factors 
  • Peptide hormone 
  • Insulin 
  • Cytokines 
  • Immunoglobin 
  • Monoclonal Antibodies

By Molecular Type

  • Small Molecule
  • Large Molecule

By Application

  • Oncology
  • Diabetes 
  • Infectious Diseases 
  • Blood Disorders 
  • Musculoskeletal Disorders 
  • Hormonal Disorders 
  • Pain Management 
  • CNS Diseases 
  • Cardiovascular Diseases

By Administration

  • Intravenous (IV)
  • Intramuscular (IM)
  • Subcutaneous (SC)

By Distribution Channel

  • Hospital pharmacy
  • Retail pharmacy
  • Drug stores
  • Online pharmacy

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

What is the current size of generic injectable market?
The global generic injectable market size was accounted at USD 94.3 billion in 2021 and it is expected to reach around USD 309.1 billion by 2030.
The global generic injectable market is poised to grow at a CAGR of 14.1% from 2022 to 2030.
The major players operating in the generic injectable market are DR. Reddys Laboratries Ltd, Baxter International, Mylan N.A, Teva Pharmaceuticals, Astra Zeneca Plc, Sanofi S.A, Fresenius Kabi, Pfizer Inc, Cipla Ltd, Merck & Co. Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Limited, Samsung Biologics Co Ltd, Biocon, Lupin,Ltd, Astrazeneca, GlaxoSmithKline Plc, Hikma Pharmaceuticals, Cosette Pharmaceutical, Inc, Johnson & Johnson Services, Inc, Sanofi SA, and others.
Rising prevalence of chronic infectious diseases, cost effectivity and increased research and developments in generic drugs are driving the growth of the generic injectable market.
North America region will lead the global generic injectable market during the forecast period 2022 to 2030.
  • Report Code:2180
  • Category:Healthcare
  • No. of Pages:150+
  • Format:PDF/PPT/Excel
  • Status:Published

PROCEED TO BUY

   USD 4500
   USD 7000
   USD 9000

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample